AU2016336929B2 - Colloidal particles for use in medicine - Google Patents

Colloidal particles for use in medicine Download PDF

Info

Publication number
AU2016336929B2
AU2016336929B2 AU2016336929A AU2016336929A AU2016336929B2 AU 2016336929 B2 AU2016336929 B2 AU 2016336929B2 AU 2016336929 A AU2016336929 A AU 2016336929A AU 2016336929 A AU2016336929 A AU 2016336929A AU 2016336929 B2 AU2016336929 B2 AU 2016336929B2
Authority
AU
Australia
Prior art keywords
composition
amphipathic lipid
glycero
dspe
factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016336929A
Other languages
English (en)
Other versions
AU2016336929A1 (en
Inventor
William Henry
John Mayo
Richard WOLF-GARRAWAY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cantab Biopharmaceuticals Patents Ltd
Original Assignee
Cantab Biopharmaceuticals Patents Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cantab Biopharmaceuticals Patents Ltd filed Critical Cantab Biopharmaceuticals Patents Ltd
Publication of AU2016336929A1 publication Critical patent/AU2016336929A1/en
Application granted granted Critical
Publication of AU2016336929B2 publication Critical patent/AU2016336929B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2016336929A 2015-10-14 2016-10-14 Colloidal particles for use in medicine Ceased AU2016336929B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1518172.0A GB201518172D0 (en) 2015-10-14 2015-10-14 Colloidal particles for use in medicine
GB1518172.0 2015-10-14
PCT/EP2016/074759 WO2017064276A1 (en) 2015-10-14 2016-10-14 Colloidal particles for use in medicine

Publications (2)

Publication Number Publication Date
AU2016336929A1 AU2016336929A1 (en) 2018-05-10
AU2016336929B2 true AU2016336929B2 (en) 2022-09-29

Family

ID=55131025

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016336929A Ceased AU2016336929B2 (en) 2015-10-14 2016-10-14 Colloidal particles for use in medicine

Country Status (15)

Country Link
US (3) US20190192664A1 (enExample)
EP (1) EP3362039A1 (enExample)
JP (1) JP7160678B2 (enExample)
KR (1) KR20180067616A (enExample)
CN (1) CN108472246A (enExample)
AU (1) AU2016336929B2 (enExample)
BR (1) BR112018007399A2 (enExample)
CA (1) CA3036111C (enExample)
EA (1) EA201890703A1 (enExample)
GB (1) GB201518172D0 (enExample)
HK (1) HK1256814A1 (enExample)
IL (1) IL258567B2 (enExample)
MX (1) MX391574B (enExample)
SG (2) SG11201802956RA (enExample)
WO (1) WO2017064276A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021092580A1 (en) * 2019-11-07 2021-05-14 The Board Of Trustees Of The University Of Illinois Peptides and methods of treating sepsis, atherosclerosis, thrombosis, stroke, heart attack and inflammation
GB202111757D0 (en) * 2021-08-17 2021-09-29 Cantab Biopharmaceuticals Patents Ltd Modified colloidal particles for use in the treatment of haemophilia A
GB202111759D0 (en) * 2021-08-17 2021-09-29 Cantab Biopharmaceuticals Patents Ltd Modified colloidal particles
GB202111758D0 (en) * 2021-08-17 2021-09-29 Cantab Biopharmaceuticals Patents Ltd Modified colloidal particles for use in the treatment of haemophilia A

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232075A1 (en) * 2002-05-06 2003-12-18 University Of Minnesota, A Minnesota Corporation Compositions for producing factor Xa
US20070141135A1 (en) * 2005-06-29 2007-06-21 Balu-Lyer Sathy V Compositions and methods for less immunogenic protein-lipid complexes
US20070167359A1 (en) * 2003-04-15 2007-07-19 Moshe Baru Pharmaceutical composition comprising proteins and/or polypeptides and colloidal particles

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
DE69418334T2 (de) 1993-08-06 2000-01-27 Opperbas Holding B.V., Amsterdam Verfahren zur hohen beladung von vesikeln mit biopolymeren substanzen
MXPA00010241A (es) 1998-04-27 2004-09-06 Opperbas Holding Bv Composicion farmaceutica que comprende el factor viii y liposomas neutrales..
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
RU2250911C2 (ru) 1999-07-14 2005-04-27 Элзэ Копэрейшн Липосомальная композиция, нейтральный липополимер и способ увеличения времени циркуляции липосомы
AU2010255391C1 (en) 2009-06-03 2016-10-27 Sequessome Technology Holdings Limited Formulations for the treatment of deep tissue pain
MX336482B (es) 2009-08-21 2016-01-21 Henk-Andre Kroon Formulaciones vesiculares.
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
GB201007357D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
EP2838566A2 (en) 2012-04-16 2015-02-25 Cantab Biopharmaceuticals Patents Limited Optimised subcutaneous therapeutic agents
CN107879960B (zh) * 2013-03-08 2021-06-22 诺华股份有限公司 用于传递活性成分的脂质和脂质组合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232075A1 (en) * 2002-05-06 2003-12-18 University Of Minnesota, A Minnesota Corporation Compositions for producing factor Xa
US20070167359A1 (en) * 2003-04-15 2007-07-19 Moshe Baru Pharmaceutical composition comprising proteins and/or polypeptides and colloidal particles
US20070141135A1 (en) * 2005-06-29 2007-06-21 Balu-Lyer Sathy V Compositions and methods for less immunogenic protein-lipid complexes

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BARU MOSHE ET AL, THROMBOSIS AND HAEMOSTASIS, SCHATTAUER GMBH, DE, (2005), vol. 93, no. 6, pages 1061-1068 *
PENG AARON ET AL, "PEGylation of a Factor VIII-Phosphatidylinositol Complex: Pharmacokinetics and Immunogenicity in Hemophilia A Mice", THE AAPS JOURNAL, SPRINGER US, BOSTON, (2011-12-16), vol. 14, no. 1, pages 35 - 42 *
YATUV R ET AL, "Binding of proteins to PEGylated liposomes and improvement of G-CSF efficacy in mobilization of hematopoietic stem cells", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 135, no. 1, (2009), pages 44 - 50. *

Also Published As

Publication number Publication date
SG10202010711UA (en) 2020-12-30
EP3362039A1 (en) 2018-08-22
CN108472246A (zh) 2018-08-31
IL258567B1 (en) 2025-04-01
WO2017064276A1 (en) 2017-04-20
CA3036111C (en) 2023-06-06
HK1256814A1 (zh) 2019-10-04
EA201890703A1 (ru) 2018-11-30
IL258567B2 (en) 2025-08-01
MX2018004445A (es) 2018-08-14
MX391574B (es) 2025-03-21
US20250170244A1 (en) 2025-05-29
SG11201802956RA (en) 2018-05-30
IL258567A (en) 2018-05-31
JP7160678B2 (ja) 2022-10-25
BR112018007399A2 (pt) 2018-10-16
AU2016336929A1 (en) 2018-05-10
CA3036111A1 (en) 2017-04-20
US20190192664A1 (en) 2019-06-27
US20210093721A1 (en) 2021-04-01
JP2018535952A (ja) 2018-12-06
GB201518172D0 (en) 2015-11-25
KR20180067616A (ko) 2018-06-20

Similar Documents

Publication Publication Date Title
US20250170244A1 (en) Colloidal particles for use in medicine
JP7573582B2 (ja) Ｐｅｇ化リポソームおよび血液凝固因子の製剤処方
WO2017064289A1 (en) Colloidal particles for topical administration with therapeutic agent
US20240366732A1 (en) Modified colloidal particles for use in the treatment of haemophilia a
WO2017064300A1 (en) Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent
US20240358801A1 (en) Modified colloidal particles for use in the treatment of haemophilia a
US20250064738A1 (en) Modified colloidal particles for use in the treatment of haemophilia a

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired